Introduction
Drug-induced dermatoses are adverse skin reactions triggered by medications, ranging from mild rashes to severe conditions like Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Understanding their prevalence, risk factors, and clinical presentations is essential for effective prevention and management. This study investigates the epidemiology, types, and risk factors associated with drug-induced dermatoses, providing insights for healthcare providers.
Materials and Methods
A comprehensive review of 125 studies (2000–2024) was conducted using databases such as MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials. Data from literature reviews, observational studies, clinical trials, and case reports were analyzed to determine the prevalence, implicated drugs, and demographic or clinical factors influencing these reactions.
Results
Drug-induced dermatoses include a spectrum of reactions from mild to life-threatening. Commonly implicated drugs are antibiotics, NSAIDs, and antiepileptics, with prevalence rates of 0.5% to 5% among high-risk drug users. Severe reactions include SJS/TEN, drug reactions with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). Significant risk factors include genetic predispositions (e.g., HLA-B*1502 for carbamazepine), age extremes, pre-existing conditions such as autoimmune diseases or HIV, and factors related to the type, dose, and duration of drug exposure.
Conclusion
Healthcare providers should identify high-risk drugs and implement measures such as genetic screening to minimize adverse reactions. Improving diagnostics, clinicians’education, and antibiotic stewardship is vital. Further research into genetic biomarkers and personalized medicine could reduce the clinical and societal impact of these reactions, enhancing patient care and outcomes.
Del Pozzo-Magaña BR, Liy-Wong C. Drugs and the skin: A concise review of cutaneous adverse drug reactions. Br J Clin Pharmacol. 2024 Aug;90(8):1838-1855. doi: 10.1111/bcp.15490.
Marzano AV, Borghi A, Cugno M. Adverse drug reactions and organ damage: The skin. Eur J Intern Med. 2016 Mar;28:17-24. doi: 10.1016/j.ejim.2015.11.017.
Al-Ahmad M, Edin J, Musa F, Rodriguez-Bouza T. Drug Allergy Profile From a National Drug Allergy Registry. Front Pharmacol. 2021 Jan 8;11:555666. doi: 10.3389/fphar.2020.555666.
Lee EY, Knox C, Phillips EJ. Worldwide Prevalence of Antibiotic-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis. JAMA Dermatol. 2023 Apr 1;159(4):384-392. doi: 10.1001/jamadermatol.2022.6378.
Balakirski G, Merk HF. Cutaneous allergic drug reactions: update on pathophysiology, diagnostic procedures and differential diagnosic. Cutan Ocul Toxicol. 2017 Dec;36(4):307-316. doi: 10.1080/15569527.2017.1319379.
Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Chem Immunol Allergy. 2012;97:1-17. doi: 10.1159/000335612.
Sánchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Risk of skin reactions when using ibuprofen-based medicines. Expert Opin Drug Saf. 2005 Sep;4(5):837-48. doi: 10.1517/14740338.4.5.837.
Kasemsarn P, Kulthanan K, Tuchinda P, Dhana N, Jongjarearnprasert K. Cutaneous reactions to non-steroidal anti-inflammatory drugs. J Drugs Dermatol. 2011 Oct;10(10):1160-7.
Błaszczyk B, Lasoń W, Czuczwar SJ. Antiepileptic drugs and adverse skin reactions: An update. Pharmacol Rep. 2015 Jun;67(3):426-34. doi: 10.1016/j.pharep.2014.11.009.
Borrelli EP, Lee EY, Descoteaux AM, Kogut SJ, Caffrey AR. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System. Epilepsia. 2018 Dec;59(12):2318-2324. doi: 10.1111/epi.14591
Kim HK, Kim DY, Bae EK, Kim DW. Adverse Skin Reactions with Antiepileptic Drugs Using Korea Adverse Event Reporting System Database, 2008-2017. J Korean Med Sci. 2020 Feb 3;35(4):e17. doi: 10.3346/jkms.2020.35.e17.
Warnock JK, Morris DW. Adverse cutaneous reactions to antipsychotics. Am J Clin Dermatol. 2002;3(9):629-36. doi: 10.2165/00128071-200203090-00005.
Jörg I, Fenyvesi T, Harenberg J. Anticoagulant-related skin reactions. Expert Opin Drug Saf. 2002 Sep;1(3):287-94. doi: 10.1517/14740338.1.3.287.
Sica DA. Angiotensin‐Converting Enzyme Inhibitors' Side Effects—Physiologic and Non‐Physiologic Considerations. J Clin Hypertens (Greenwich). 2007 May 25;7(Suppl 8):17–23. doi: 10.1111/j.1524-6175.2005.04556.x.
Martínez JC, Fuentes MJ, Armentia A, Vega JM, Fernández A. Dermatitis to captopril. Allergol Immunopathol (Madr). 2001 Nov-Dec;29(6):279-80. doi: 10.1016/s0301-0546(01)79071-4.
Deen J, Oakley A, Mitchell G. 2019 Cutaneous adverse reactions to calcineurin inhibitors | DermNet NZ [Internet]. dermnetnz.org. Available from: https://dermnetnz.org/topics/cutaneous-adverse-reactions-to-calcineurin-inhibitors
Chaudhary RG, Rathod SP, Jagati A, Zankat D, Brar AK, Mahadevia B. Oral Antifungal Therapy: Emerging Culprits of Cutaneous Adverse Drug Reactions. Indian Dermatol Online J. 2019 Mar-Apr;10(2):125-130. doi: 10.4103/idoj.IDOJ_353_18.
Sharma RK, Verma GK, Tegta GR, Sood S, Rattan R, Gupta M. Spectrum of Cutaneous Adverse Drug Reactions to Anti-tubercular Drugs and Safe Therapy after Re-challenge - A Retrospective Study. Indian Dermatol Online J. 2020 Mar 9;11(2):177-181. doi: 10.4103/idoj.IDOJ_133_19
HIV and Rash | NIH [Internet]. hivinfo.nih.gov. Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-rash
Scavone C, Di Mauro C, Ruggiero R, Bernardi FF, Trama U, Aiezza ML, et al. Severe Cutaneous Adverse Drug Reactions Associated with Allopurinol: An Analysis of Spontaneous Reporting System in Southern Italy. Drugs Real World Outcomes. 2020 Mar;7(1):41-51. doi: 10.1007/s40801-019-00174-7.
Saini K, Sutaria A, Shah B, Brahmbhatt V, Parmar K. Cutaneous Adverse Drug Reactions to Targeted Chemotherapeutic Drugs: A Clinico-Epidemiological Study. Indian J Dermatol. 2019 Nov-Dec;64(6):471-475. doi: 10.4103/ijd.IJD_491_18.
Sehgal R, Stratman EJ, Cutlan JE. Biologic Agent-Associated Cutaneous Adverse Events: A Single Center Experience. Clin Med Res. 2018 Jun;16(1-2):41-46. doi: 10.3121/cmr.2017.1364.
Böhm R, Cascorbi I. Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions. Front Pharmacol. 2016 Oct 21;7:396. doi: 10.3389/fphar.2016.00396.
Nayak S, Acharjya B. Adverse cutaneous drug reaction. Indian J Dermatol. 2008 Jan;53(1):2-8. doi: 10.4103/0019-5154.39732.
Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol. 2011 May;71(5):684-700. doi: 10.1111/j.1365-2125.2010.03774.x.
Email this article (Login required) 
